An increased abundance of eicosapentaenoic acid is associated with a reduced risk of heart failure, and this protective effect is independent of established risk factors and ejection fraction status, according to a study presented at the 2018 American Heart Association (AHA) Scientific Sessions in Chicago, Illinois, US.
The use of low-dose intracoronary alteplase, a tissue plasminogen activator (tPA), in patients with acute ST-elevation myocardial infarction (STEMI) at the time of primary percutaneous coronary intervention (PCI) was ineffective in reducing microvascular obstruction (MVO, or failed myocardial reperfusion), according to the T-TIME* trial results presented at AHA 2018.
Treatment with the SGLT2i* empagliflozin appears to significantly reduce left ventricular mass (LVM) among patients with type 2 diabetes (T2D), according to results of the EMPA-HEART** CardioLink-6 trial presented at AHA 2018.
Coronary revascularization with bypass surgery proves to be superior to drug eluting stents in the long term in preventing all-cause mortality in patients with diabetes mellitus (DM) and multivessel coronary disease (MVD), even 8 years after the procedure, the FREEDOM* Follow-On Study reveals.
Dapagliflozin reduced the risk of hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) who had established or multiple risk factors for atherosclerotic cardiovascular disease (CVD), according to results of the DECLARE-TIMI 58* trial presented at AHA 2018. However, it did not reduce the incidence of major adverse cardiovascular events (MACE)**.
Lipid-lowering with ezetimibe monotherapy was effective for the primary prevention of atherosclerotic cardiovascular (CV) events in middle- to high-risk elderly Japanese patients with hypercholesterolaemia, according to the EWTOPIA75* study presented at AHA 2018 Scientific Sessions.
Supplementation with either omega-3 fatty acids (ie, fish oil) or vitamin D did not reduce the incidence of major cardiovascular (CV) events (ie, composite of myocardial infarction [MI], stroke, and CV death) or total invasive cancer, according to the VITAL* trial presented at AHA 2018.
The administration of sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, during hospitalization significantly reduces the N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels among patients with acute decompensated heart failure (ADHF) and reduced ejection fraction compared with enalapril, according to the PIONEER-HF* trial presented at AHA 2018 Scientific Sessions.
Low-dose methotrexate, which is approved for the treatment of rheumatoid arthritis (RA) and other autoimmune disorders, has shown unexpectedly disappointing results in preventing cardiovascular (CV) events among patients with a prior myocardial infarction (MI) or multivessel coronary disease, according to CIRT*, potentially ruling out what could be an affordable option for treating inflammation related to atherosclerosis.
New drug applications approved by US FDA as of 16 - 30 November 2018
which includes New Molecular Entities (NMEs) and new biologics. It does
not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony,
01 Oct 2019
The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.
Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.